About Prosensa
Prosensa is a company based in Leiden (Netherlands) founded in 2002 was acquired by BioMarin Pharmaceutical in November 2014. Prosensa has raised $72.62 million across 4 funding rounds from investors including BioMarin Pharmaceutical, Idinvest Partners and Gimv. Prosensa operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Denali Therapeutics, Neurocrine and PTC Therapeutics, among others.
- Headquarter Leiden, Netherlands
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Prosensa Holding N.V.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$72.62 M (USD)
in 4 rounds
-
Latest Funding Round
$200 K (USD), Grant
Jun 27, 2014
-
Investors
BioMarin Pharmaceutical
& 7 more
-
Employee Count
Not available
-
Acquired by
BioMarin Pharmaceutical
(Nov 24, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Prosensa
Prosensa has successfully raised a total of $72.62M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $200 thousand completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Prosensa
Prosensa has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include BioMarin Pharmaceutical, Idinvest Partners and Gimv.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Private equity firm
|
Locked | Locked | Locked |
Investor details for Prosensa
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Prosensa
Investment portfolio details for Prosensa
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Prosensa
Detailed financials for Prosensa
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Prosensa Comparisons
Peer comparison for Prosensa
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Prosensa
Prosensa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Denali Therapeutics, Neurocrine and PTC Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Prosensa
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prosensa
Complete news archive for Prosensa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prosensa
Prosensa was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Prosensa is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Prosensa is a funded company, having raised a total of $72.62M across 4 funding rounds to date.
Prosensa was founded in 2002 in Leiden, Netherlands, within the biotechnology sector. Focus was placed on RNA-modulating therapeutics for neuromuscular disorders, including the lead compound drisapersen, an oligonucleotide targeting dystrophin RNA splicing for Duchenne muscular dystrophy across seven programs. Preclinical candidates were advanced for Huntingtons disease and myotonic dystrophy. Acquisition by BioMarin occurred in November 2014.
Prosensa's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Prosensa has 8 investors. Key investors include BioMarin Pharmaceutical, Idinvest Partners, Gimv, Abingworth, and Life Sciences Partners.